Kiora Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGKiora Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 64), indicating performance broadly in line with the market. Earnings growth of 101% provides fundamental context to the price action. Investors should exercise caution due to high volatility (74% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $2.44 | +0.29% | ABOVE |
| 50 SMA | $2.23 | +9.86% | ABOVE |
| 100 SMA | $2.18 | +12.59% | ABOVE |
| 150 SMA | $2.23 | +10.01% | ABOVE |
| 200 SMA | $2.34 | +4.72% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is KPRX in an uptrend right now?
KPRX has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is KPRX overbought or oversold?
KPRX's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is KPRX outperforming the market?
KPRX has a Relative Strength (RS) Rating of 64 out of 99. KPRX is performing about average compared to the market.
Where is KPRX in its 52-week range?
KPRX is trading at $2.45, which is 59% of its 52-week high ($4.18) and 29% above its 52-week low ($1.76).
How volatile is KPRX?
KPRX has a Beta of 1.29 and 52-week volatility of 74%. It's more volatile than the S&P 500 - expect bigger swings.